The biotech company best known for its COVID-19 vaccine has become the S&P 500’s best-performing stock of 2026, with shares up more than 650% year to date. Moderna’s market cap has climbed to roughly $89 billion, a dramatic rebound for a company that entered the year valued at a fraction of that.⁠ ⁠ The rally has accelerated as investors turn their attention to Moderna’s oncology pipeline, particularly its cancer vaccine work with Merck. Shares more than doubled in a single session in August after new cancer-vaccine data, adding roughly $30 billion in market value at the time.⁠ ⁠ The momentum has also pushed Moderna back into the Nasdaq-100, with the company officially joining the index today, replacing Warner Bros. Discovery.⁠ ⁠ (via @Yahoo Finance) #finance #stocks #topperformance #wallstreet #moneytok